Biotechnology Innovation Organization (Bio)
Trade association
Based in DC
AI Overview
With $2.3M in lobbying spend across 32 quarterly filings, Biotechnology Innovation Organization (Bio) is a significant lobbying presence. Their lobbying covers 7 issue areas. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $240K |
| 2019 | $300K |
| 2020 | $240K |
| 2021 | $320K |
| 2022 | $320K |
| 2023 | $320K |
| 2024 | $320K |
| 2025 | $240K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Taxation, Medicare/Medicaid, Animals, Health Issues, Budget/Appropriations and 2 more
- Biofuels, renewable chemicals/bio-based products
- Issues related to reimbursement under Medicare Part B generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
- Issues related to Medicare Part D, generally; Bipartisan Budget Act (H.R. 1892); Consolidated Appropriations Act (H.R. 1625)
- Medicaid; drug benefit design; pricing and rebates; and Section 1115 waivers
- Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act of 2018; amendment on GE Salmon Labeling
- Issued relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); and the Ensuring the Value of the 340B Program Act (S. 2453)
- Biodefense research, development and procurement issues; Pandemic All Hazards Preparedness Act (PAHPA) reauthorization; pandemic flu; MCM priority review voucher program
- Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
- Drug evaluation and review; compassionate use expanded access; Right to Try Act of 2017 (H.R. 878/S. 204); expedited pathways; innovation incentives; implementation of PDUFA IV and BSUFA II
- Issues related to drug pricing and value, generally; Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
- Vaccines and infectious diseases; antimicrobials
- Funding for Antimicrobial Resistance Programs
- Funding for biofuels; Farm Bill Reauthorization
- Funding for Biodefense and Emergency Preparedness Research, Development and Procurement, including reauthorization of the Pandemic All-Hazards Preparedness Act
Vaccines and infectious diseases; antimicrobials
Issues related to reimbursement under Medicare Part B generally
Issues related to Medicare Part D, generally
Medicaid; drug benefit design; pricing and rebates; and Section 1115 waivers
Showing 8 of 20 unique descriptions from filings.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.